Our healthcare solutions revenue grew almost about 37% organically in the quarter as we continued on the double-digit growth trajectory we started to see in the third quarter. Overall, our organic revenue growth was 7.6% in the quarter and for the full-year.Decision Analytics organic growth in Q4 was 11%, driven by both strong growth from insurance-facing solutions as well as the accelerated growth in healthcare. The mortgage market remained challenging with the macroeconomic conditions continuing to work against us. We continue to have conviction around our margin and overall profitability. We are pleased to deliver 25% growth in diluted adjusted EPS for 2011 and over 16% growth in EBITDA, while expanding margins to over 46% excluding the recent acquisitions.
Verisk Analytics CEO Discusses Q4 2011 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.